Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

DIVE into AD

Financiado

Cerrado

Study of tau strains to understand the phenotypic diversity of Alzheimer s disea...

Study of tau strains to understand the phenotypic diversity of Alzheimer s disease A step toward personalized therapies Dementia represents a major challenge for our ageing societies. The number of citizens suffering from dementia in the EU is expected to reach 19 millions by 2050. Alzheimer’s disease (AD) is responsible for the vast majority of de... ver más

04/01/2023

UNIGE

190K€

Presupuesto del proyecto: 190K€

Líder del proyecto

UNIVERSITE DE GENEVE No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 3 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2023-01-04

MSCA-IF-2018: Individual Fellowships

I+D

Cerrada hace 6 años

0% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

3 Participantes

UNIGE

190.21K€ | Lider

THE GENERAL HOSPITAL CORPORA...

88.63K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

AMYLOID Identification and modulation of pathogenic Amyloid beta pep... 2M€ Cerrado

TAU-NOW Tau Pathology in Alzheimer s disease Spreading and Resilien... 2M€ Cerrado

ALZSYN Imaging synaptic contributors to dementia 2M€ Cerrado

MODULADORES DE LA BIOPATOLOGIA DEL PEPTIDO B... MODULADORES DE LA BIOPATOLOGIA DEL PEPTIDO B AMILOIDE COMO F... 4M€ Cerrado

PCI2021-122108-2B TARGETING THE INITIAL STAGE OF ALZHEIMER S DISEASE: BLOCKING... 161K€ Cerrado

RTI2018-095753-B-I00 VALIDACION DE UNA NUEVA ESTRATEGIA TERAPEUTICA PARA TRATAR A... 109K€ Cerrado

Duración del proyecto: 44 meses Fecha Inicio: 2019-04-30
Fecha Fin: 2023-01-04

Líder del proyecto

UNIVERSITE DE GENEVE No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 190K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Dementia represents a major challenge for our ageing societies. The number of citizens suffering from dementia in the EU is expected to reach 19 millions by 2050. Alzheimer’s disease (AD) is responsible for the vast majority of dementia cases. However there is still not a single available treatment that modifies the course of disease. Therefore, the development of innovative approaches to better understand the pathophysiology and ultimately treat patients must be a priority. This project aims to understand the determinants of the diversity of AD clinical phenotypes through the deep analysis of pathological variants of the tau protein. As the accumulation of Aβ peptide has long been considered a causative event in AD, most therapeutic approaches have targeted Aβ metabolism, but unsuccessfully. Modern biomarkers, have confirmed that the brain deposition of tau pathology, the other hallmark of AD, correlates much better with human cognition and neurodegeneration. Recently, it was shown that tau behaves like a prion and can spread from one neuron to another. Moreover, tau strains or conformers seem to template native tau and propagate the pathological conformation with high fidelity. Discrete tau strains generate distinct aggregates morphology or patterns of neuronal vulnerability. I postulate that different strains of tau are responsible for the variability of AD and may determine the progression rate, gender differences or clinical expression. Therefore, my objective is to develop the technologies to identify tau strains signatures in distinct AD phenotypes. In particular, I plan to develop and optimize biosensor cell lines that sensitively detect tau strains from human brain samples and cerebrospinal fluid, and characterize respective repertoire of tau strains. Understanding AD heterogeneity would potentially increase our ability to take care of every individual patient. In addition, this work could lead to the development of biomarkers and novel targeted therapies.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores